Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Sequenom Secures $33M Through Private Stock Placement

NEW YORK, June 7 (GenomeWeb News) - Sequenom yesterday said it secured $33 million in a private stock placement with four institutional investors.

 

Sequenom shareholders approved the placement and a reverse stock split last month. The stock split went into effect last week.

 

As part of the placement, Sequenom sold or issued around 20 million shares of common stock and warrants to purchase an additional 12 million shares.

 

The investors were Pequot Private Equity Fund, ComVest Investment Partners, LB I Group, and Siemens Venture Capital. Oppenheimer & Co. served as the placement agent.

 

Sequenom said it will use the cash for general working capital purposes, to "strengthen and expand" its core product sales and services business, and pursue opportunities in the field of non-invasive prenatal diagnostics.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more